Evicenter
MarkdownMedical informationP&T meetings
Rinzimetostat (ORIC-944)

Metastatic castration-resistant prostate cancer previously treated with abiraterone, in combination with darolutamide

Regulatory status
Not announced
Launch
Not announced
Last updated
165 sources

Product information and disease descriptionProduct descriptionProduct information

Special populations

10 evidence topics · 4 sources